Cost-effectiveness: maximizing impact by meticulous data

Hedwig M. Blommestein; Sonja Zweegman

doi:10.1182/blood.2022016958

Cost-effectiveness: maximizing impact by meticulous data

Hedwig M. Blommestein
, Sonja Zweegman

Health Technology Assessment (HTA)

Amsterdam UMC
Cancer Center Amsterdam (CCA)

Research output: Contribution to journal › Editorial › Academic › peer-review

2 Citations (Scopus)

84 Downloads (Pure)

Original language	English
Pages (from-to)	525-526
Number of pages	2
Journal	Blood
Volume	140
Issue number	6
DOIs	https://doi.org/10.1182/blood.2022016958
Publication status	Published - 11 Aug 2022

Bibliographical note

Funding Information:
Conflict-of-interest disclosure: H.M.B. reports consulting or advisory role for Pfizer (paid to institute) and research funding from BMS-Celgene (paid to institute). S.Z. reports consulting or advisory role for BMS, Janssen-Cilag, Takeda, Sanofi, and Oncopeptides (all paid to institute) and research funding from Janssen-Cilag and Takeda (all paid to institute).

Funding Information:
Conflict-of-interest disclosure: H.M.B. reports consulting or advisory role for Pfizer (paid to institute) and research funding from BMS-Celgene (paid to institute). S.Z. reports consulting or advisory role for BMS, Janssen-Cilag, Takeda, Sanofi, and Oncopeptides (all paid to institute) and research funding from Janssen-Cilag and Takeda (all paid to institute).

Access to Document

10.1182/blood.2022016958

Cost-effectiveness maximizing impact by meticulous datFinal published version, 565 KB

Cite this

@article{c958fae4a9734abca9c586cc913d418d,

title = "Cost-effectiveness: maximizing impact by meticulous data",

author = "Blommestein, \{Hedwig M.\} and Sonja Zweegman",

note = "Funding Information: Conflict-of-interest disclosure: H.M.B. reports consulting or advisory role for Pfizer (paid to institute) and research funding from BMS-Celgene (paid to institute). S.Z. reports consulting or advisory role for BMS, Janssen-Cilag, Takeda, Sanofi, and Oncopeptides (all paid to institute) and research funding from Janssen-Cilag and Takeda (all paid to institute). Funding Information: Conflict-of-interest disclosure: H.M.B. reports consulting or advisory role for Pfizer (paid to institute) and research funding from BMS-Celgene (paid to institute). S.Z. reports consulting or advisory role for BMS, Janssen-Cilag, Takeda, Sanofi, and Oncopeptides (all paid to institute) and research funding from Janssen-Cilag and Takeda (all paid to institute). ",

year = "2022",

month = aug,

day = "11",

doi = "10.1182/blood.2022016958",

language = "English",

volume = "140",

pages = "525--526",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Cost-effectiveness

T2 - maximizing impact by meticulous data

AU - Blommestein, Hedwig M.

AU - Zweegman, Sonja

N1 - Funding Information: Conflict-of-interest disclosure: H.M.B. reports consulting or advisory role for Pfizer (paid to institute) and research funding from BMS-Celgene (paid to institute). S.Z. reports consulting or advisory role for BMS, Janssen-Cilag, Takeda, Sanofi, and Oncopeptides (all paid to institute) and research funding from Janssen-Cilag and Takeda (all paid to institute). Funding Information: Conflict-of-interest disclosure: H.M.B. reports consulting or advisory role for Pfizer (paid to institute) and research funding from BMS-Celgene (paid to institute). S.Z. reports consulting or advisory role for BMS, Janssen-Cilag, Takeda, Sanofi, and Oncopeptides (all paid to institute) and research funding from Janssen-Cilag and Takeda (all paid to institute).

PY - 2022/8/11

Y1 - 2022/8/11

UR - https://www.scopus.com/pages/publications/85135927594

U2 - 10.1182/blood.2022016958

DO - 10.1182/blood.2022016958

M3 - Editorial

C2 - 35951343

AN - SCOPUS:85135927594

SN - 0006-4971

VL - 140

SP - 525

EP - 526

JO - Blood

JF - Blood

IS - 6

ER -

Cost-effectiveness: maximizing impact by meticulous data

Bibliographical note

Access to Document

Other files and links

Cite this